Effect of dual drug therapy with coamoxiclav-based on Helicobacter pylori eradication

Assessment of dual drug therapy effect with coamoxiclav-based on Helicobacter pylori eradication

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201213049694N1

Enrollment

188

Registered

2020-12-15

Start date

2020-09-22

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection. Helicobacter pylori [H. pylori] as the cause of diseases classified elsewhere

Interventions

Intervention 1: Intervention group: The two-drug regimen consists of amoxicillin 500 mg twice daily with coamoxiclav 625 mg twice daily and rabizol four times daily for two weeks, after that, antibiot

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Helicobacter pylori serology test is positive Severe disorders affecting the gastrointestinal tract

Exclusion criteria

Exclusion criteria: Gastrointestinal malignancy Pregnant and lactating History of radiotherapy Allergy to any of the antibiotics used in the study Active gastrointestinal bleeding

Design outcomes

Primary

Measure	Time frame
Helicobacter pylori eradication. Timepoint: After 2weeks of completion of treatment. Method of measurement: Urea breath test.	—

Secondary

Measure	Time frame
Drug Side effects. Timepoint: During and after the course of treatment. Method of measurement: Ask the patient.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Reza Pashaei

Oroumia University of Medical Sciences

dr.pashaei@yahoo.com+98 44 3346 9931

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026